EMA Q&A Consultation procedure to EMA by NBs on ancillary medicinal substance/human blood derivative in medical device, 03/21 Beatrice Burtsov2022-01-26T15:52:17+00:00January 26th, 2022| About the Author: Beatrice Burtsov